Actinium Pharmaceuticals (NYSE:ATNM) Price Target Cut to $5.00

Actinium Pharmaceuticals (NYSE:ATNM) had its price objective cut by Maxim Group from $30.00 to $5.00 in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also recently issued reports on ATNM. Cantor Fitzgerald reaffirmed an overweight rating and set a $21.00 price target on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 30th. HC Wainwright reissued a buy rating and set a $50.00 price target on shares of Actinium Pharmaceuticals in a research note on Friday, July 26th. StockNews.com downgraded Actinium Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, August 5th. Finally, Stephens started coverage on Actinium Pharmaceuticals in a research report on Tuesday, May 14th. They set an overweight rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $11.43.

Actinium Pharmaceuticals Stock Down 14.9 %

ATNM traded down $0.36 on Tuesday, hitting $2.05. 890,374 shares of the company traded hands, compared to its average volume of 484,717. Actinium Pharmaceuticals has a 12-month low of $1.33 and a 12-month high of $10.24. The company has a market cap of $61.06 million, a PE ratio of -1.19 and a beta of 0.20.

Actinium Pharmaceuticals (NYSE:ATNM) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.02. As a group, sell-side analysts expect that Actinium Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Large investors have recently modified their holdings of the stock. Sanders Morris Harris LLC bought a new stake in Actinium Pharmaceuticals during the first quarter valued at $78,000. Virtu Financial LLC raised its position in shares of Actinium Pharmaceuticals by 319.2% during the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after purchasing an additional 62,459 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Actinium Pharmaceuticals in the 2nd quarter worth approximately $142,000. Rhumbline Advisers boosted its position in Actinium Pharmaceuticals by 23.4% during the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after purchasing an additional 7,525 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in Actinium Pharmaceuticals by 28.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock worth $639,000 after buying an additional 19,035 shares during the last quarter. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.